Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Gross Margin (2016 - 2019)

Cardiff Oncology's Gross Margin history spans 7 years, with the latest figure at 100.0% for Q4 2019.

  • For Q4 2019, Gross Margin changed 0.0% year-over-year to 100.0%; the TTM value through Dec 2019 reached 100.0%, up 15792.0%, while the annual FY2019 figure was 100.0%, 15792.0% up from the prior year.
  • Gross Margin for Q4 2019 was 100.0% at Cardiff Oncology, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 482.0% in Q4 2017 and bottomed at 3204.34% in Q3 2016.
  • The 5-year median for Gross Margin is 215.37% (2015), against an average of 620.7%.
  • The largest annual shift saw Gross Margin plummeted -300514bps in 2016 before it skyrocketed 291962bps in 2017.
  • A 5-year view of Gross Margin shows it stood at 199.2% in 2015, then crashed by -666bps to 1524.98% in 2016, then skyrocketed by 132bps to 482.0% in 2017, then plummeted by -79bps to 100.0% in 2018, then changed by 0bps to 100.0% in 2019.
  • Per Business Quant, the three most recent readings for CRDF's Gross Margin are 100.0% (Q4 2019), 100.0% (Q3 2019), and 100.0% (Q2 2019).